Effect of TNF antagonists on the T-lymphocyte response.
Emilie
Dominique
D
INSERM U764, Paris-South University, Microbiology/Biological Immunology Department, Antoine Béclère Teaching Hospital, AP-HP, 32 rue des Carnets, 92140 Clamart, France. dominique.emilie@u-psud.fr
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000942:Antigens, Bacterial / Q000276:immunology; D002478:Cells, Cultured; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects; D000069285:Infliximab; D009169:Mycobacterium tuberculosis / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D014376:Tuberculosis / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000942:Antigens, Bacterial; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept